Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | BRS3 | P32247 | 5/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12302501 | 0.82 | CYP3A4 (0.39) | CYP3A4MAP4K1 | |
| SCHEMBL2447905 | 0.81 | MAP3K11 (0.41) | CYP3A4ABL1ALOX5APMAP4K1 | |
| SCHEMBL1702611 | 0.81 | CYP3A4 (0.39) | CYP3A4AXLMAP4K1AAK1 | |
| SCHEMBL1703346 | 0.81 | CYP3A4 (0.42) | CYP3A4ABL1 | |
| SCHEMBL12331953 | 0.81 | CYP3A4 (0.40) | CYP3A4ABL1 | |
| SCHEMBL1702764 | 0.80 | CYP3A4 (0.57) | CYP3A4 | |
| SCHEMBL1702817 | 0.77 | CYP3A4 (0.41) | CYP3A4IDO1 | |
| SCHEMBL1702735 | 0.76 | CYP3A4 (0.47) | CYP3A4ALOX5AP | |
| SCHEMBL2450318 | 0.74 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL12302402 | 0.73 | CYP3A4 (0.49) | CYP3A4BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | claimed |
| EP-2440528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | claimed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | claimed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | claimed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | CYP3A4 50/4885BRS3 2665/4885AXL 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.